stock

Abbvie Inc (ABBV)

Share

Stay up to date

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Financial Statements

Key Info

  • Industry: Pharmaceutical Preparation Manufacturing
  • Sector: Manufacturing
  • CEO Name: Richard Gonzalez

Key Statistics

  • Stock Price: $164.4
  • Dividend Yield: 3.5999999999999996%
  • Market Capitalization: $295,038,000,000
  • Shares Outstanding: 1,800,000,000
  • Number of Employees: 50,000
  • Trailing 12-Month EPS: $3.65
  • Trailing 12-Month DPS: $5.9
  • Payout Ratio: 161.60000000000002%

Important Dates

  • Next Earnings Date: 2024-02-02
  • Next Ex-Dividend Date: 2024-01-12

Price Trends

  • Current Stock Price: $164.4
  • 52-week high: $167.95
  • 52-week low: $127.03
  • 200-day moving average: $147.42
  • 50-day moving average: $158.49

Performance

  • 1-Month Price Return: 6.8%
  • 3-Month Price Return: 19.1%
  • 6-Month Price Return: 10.8%
  • 1-Year Price Return: 16.6%
  • 2-Year Price Return: 28.4%
  • 5-Year Price Return: 166.5%

Visit the Passiv Stock Directory

Data provided by IEX Cloud

For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast